St. Jude’s Epic Year Wins Over Investors; MDDI Index Up 15% In 2004
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical's entry into the cardiac resynchronization therapy ICD market and expanded atrial fibrillation business helped capture the attention of Wall Street and potential suitors in 2004 as its stock jumped 37% for the year
You may also be interested in...
St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15
St. Jude Fortifies AF Business With HIFU Market Development, R&D Initiatives
The president of St. Jude Medical's fledgling AF division, Jane Song, is tasked with establishing 10-15 "centers of excellence" in preparation for the firm's high intensity focused ultrasound (HIFU) launch
St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: